StockWatch
·
Biotechnology: Pharmaceutical Preparations
DelistingNov 20, 2026, 04:52 PM

Biofrontera Inc. Faces Nasdaq Delisting Warning Over Low Stock Price

AI Summary

Biofrontera Inc. received a notification from Nasdaq indicating non-compliance with continued listing rules due to its common stock closing below $1.00 for 30 consecutive business days. The company has 180 days, until May 17, 2027, to regain compliance by having its stock close at $1.00 or higher for 10 consecutive business days. Failure to comply may result in delisting, though the company may appeal or seek additional time through measures like a reverse stock split. Biofrontera intends to monitor its stock price and explore options to resolve the deficiency.

Key Highlights

  • Biofrontera Inc. received a non-compliance notice from Nasdaq for its common stock trading below $1.00 for 30 consecutive days.
  • The company has 180 days, until May 17, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
  • Compliance requires the stock's closing bid price to be at least $1.00 for 10 consecutive business days.
  • Potential delisting may occur if compliance is not achieved within the specified period.
  • Biofrontera may be eligible for additional time and can consider a reverse stock split to cure the deficiency.